Clinical Trials Browser

Phase 2 × Abatacept × Clear all

Graft vs Host Disease, Neoplasms

NCT03680092 2025-10-02

Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation

Phase 2 Completed

43 enrolled 10 charts

Other hematologic neoplasm

Graft vs Host Disease, Neoplasms, Hematologic Neoplasms

NCT06680661 2025-06-04

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

Phase 2 Recruiting

20 enrolled

LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03457142 2025-03-04

Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy

Phase 2 Terminated

15 enrolled 12 charts

Plasma cell

Multiple Myeloma

NCT01012492 2019-11-21

Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT

Phase 2 Completed

11 enrolled 10 charts

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Leukemia, Myelodysplastic Syndromes, Neoplasms

Clinical Trials

Abatacept as GVHD Prophylaxis Phase 2

Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy

Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT